NEW YORK, January 2, 2026, 3:30 PM ET — Regular session
- ISRG is down about 1% in afternoon trading, after swinging between the day’s low and high.
- The broader market is mixed, with healthcare slightly higher but medical-device stocks softer.
- Investors are watching next week’s U.S. jobs and inflation data, plus mid-January healthcare conference updates.
Intuitive Surgical shares slid 1% to $560.61 in afternoon trading on Friday, lagging a mixed U.S. tape in the market’s first session of 2026.
The drop matters because investors are starting the year with fresh sensitivity to valuation—how much they are paying for a dollar of earnings—after a strong 2025 run left many stocks priced for good news.
“Stocks trade expensive on 18 of 20 measures, and we see elevated risks to the index level in the near term,” Savita Subramanian, Bank of America’s equity and quant strategist, said in a note. Reuters
The S&P 500-tracking SPDR S&P 500 ETF was up 0.2%, while the Nasdaq 100-tracking Invesco QQQ ETF was down 0.1%, underscoring the uneven start to the year.
Within healthcare, the Health Care Select Sector SPDR ETF rose about 0.3%, but the iShares U.S. Medical Devices ETF slipped about 0.4%.
Peers were mixed. Medtronic shares rose about 0.3%, while Stryker fell about 0.8%, leaving Intuitive’s decline looking more stock-specific than purely sector-driven.
A regulatory filing showed that Intuitive’s Chief Digital Officer, Brian E. Miller, transitioned effective Jan. 1 to become head of digital and AI strategy, no longer reporting directly to the CEO.
Intuitive, based in Sunnyvale, California, develops the da Vinci surgical systems used for minimally invasive procedures and the Ion endoluminal system used for lung biopsy procedures, according to its filings.
On Friday, ISRG traded between $555.58 and $570.51, suggesting investors were active on both sides ahead of a busy January catalyst calendar.
Macro data is one near-term swing factor. Reuters reported the U.S. employment report is due Jan. 9, with investors watching for signals that could shift expectations for interest-rate policy.
Inflation data is close behind. The U.S. consumer price index is due Jan. 13, and fourth-quarter earnings season ramps up in the same window, raising the bar for richly valued stocks.
In healthcare, investors also look to the J.P. Morgan Healthcare Conference in San Francisco on Jan. 12–15, where companies often reset investor expectations early in the year.
